What’s the current market cap for Pediatrix Medical Group stock?

Pediatrix Medical Group (MD) has a market cap of $1.9bn as of June 12, 2026.

What is the P/E ratio for Pediatrix Medical Group stock?

The price to earnings (P/E) ratio for Pediatrix Medical Group (MD) stock is 11.7 as of June 12, 2026.

Does Pediatrix Medical Group stock pay dividends?

No, Pediatrix Medical Group (MD) stock does not pay dividends to its shareholders as of June 12, 2026.

When is the next Pediatrix Medical Group dividend payment date?

Pediatrix Medical Group (MD) stock does not pay dividends to its shareholders.

What is the beta indicator for Pediatrix Medical Group?

Pediatrix Medical Group (MD) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Pediatrix Medical Group stock | $MD Share Price

About Pediatrix Medical Group

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Ticker

$MD

Sector

Health

Primary listing

NYSE

Employees

4,280

Headquarters

Sunrise, United States

Website

www.pediatrix.com

MD Metrics

BasicAdvanced

$1.9bn

11.70

$2.06

0.71

-

What the Analysts think about MD

Analyst ratings (Buy, Hold, Sell) for Pediatrix Medical Group stock.

Bulls say / Bears say

Q1 2026 revenue rose 3.9% year-over-year to $476.2 million, surpassing market expectations (Yahoo Finance) (Yahoo Finance).

Adjusted EBITDA for Q1 2026 was $58.15 million, 11.3% above analyst forecasts, with margins improving to 12.2% (Yahoo Finance) (Yahoo Finance).

Management reiterated their full-year 2026 adjusted EBITDA outlook of $280 million–$300 million, signaling confidence in operational stability (Yahoo Finance) (Yahoo Finance).

Operating cash used increased to $129.5 million in Q1 2026, up from $116.1 million in Q1 2025, highlighting greater pressure on cash flow (Yahoo Finance) (Yahoo Finance).

The 2026 guidance anticipates flat revenue at $1.9 billion, pointing to limited growth for the top line (StockAnalysis.com) (StockAnalysis).

Management noted higher clinician compensation and some softness in volumes, both of which could put pressure on margins (TipRanks) (TipRanks).

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

MD Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

MD Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

MD News

AllArticlesVideos

HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup

Business Wire·1 week ago

Passkey Therapeutics Appoints Mandeep Kaur, MD, MS, as Chief Medical Officer to Advance Clinical Validation of Its Computational Genetics-Based Novel Drug Combination Platform

Business Wire·3 weeks ago

Pediatrix Medical Group Q1 Earnings Call Highlights

MarketBeat·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.